Evenity (Romosozumab) and Imaging Contrast Dye Interaction

What Is Romosozumab and How Does It Work?

Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. Blocking sclerostin simultaneously increases bone formation markers and decreases bone resorption markers, a dual effect not seen with bisphosphonates or denosumab. The FDA approved it in April 2019 under the brand name Evenity for postmenopausal women at high risk of fracture. [1]

Mechanism and Pharmacokinetics

The drug is given as two sequential 105 mg subcutaneous injections (210 mg total) once monthly, for a maximum of 12 months. After subcutaneous dosing, romosozumab reaches peak serum concentration in approximately 5 days and has a mean terminal half-life of about 6.4 days. [1] Because it is a biologic cleared through nonspecific immunoglobulin pathways rather than hepatic CYP450 enzymes or renal tubular secretion, classic small-molecule drug interactions do not apply in the usual sense.

Black-Box Cardiovascular Warning

The FDA label carries a boxed warning for serious cardiovascular events. In the ARCH trial (N=4,093), romosozumab was associated with a higher rate of serious cardiac ischemic events compared with alendronate (2.5% vs. 1.9%; adjudicated). [2] This cardiovascular signal directly shapes how clinicians approach contrast-enhanced imaging in patients on Evenity.

Does Romosozumab Interact With Imaging Contrast Dye?

No direct pharmacokinetic interaction between romosozumab and either iodinated contrast agents or gadolinium-based contrast agents (GBCAs) has been reported in peer-reviewed literature, the FDA prescribing information, or the European Medicines Agency summary of product characteristics. The two drug classes act through entirely different biological pathways and are cleared by different mechanisms. [1]

"no pharmacokinetic interaction" is not the same as "no clinical concern." Two overlapping risk domains require evaluation before any contrast imaging procedure in a patient on Evenity.

Risk Domain 1: Cardiovascular Status and Iodinated Contrast

Iodinated contrast media used in CT angiography, coronary angiography, and contrast-enhanced CT can transiently stress the cardiovascular system through osmotic load and direct vasomotor effects. Because romosozumab carries a boxed warning for myocardial infarction and stroke, patients on the drug already have an elevated baseline cardiovascular risk flag. [1][2]

The American College of Radiology (ACR) Manual on Contrast Media recommends pre-procedure cardiovascular risk stratification for patients receiving high-osmolality or large-volume iodinated contrast. [3] For patients currently on romosozumab, this stratification is especially relevant. Any patient who has had a myocardial infarction or stroke within the preceding 12 months should not be starting romosozumab at all per the FDA label, which means the highest-risk cardiac patients are theoretically excluded from active Evenity therapy. [1]

Practical steps before iodinated contrast in a patient on Evenity:

• Confirm no MI or stroke in the past 12 months.
• Review current antiplatelet or anticoagulant use.
• Check baseline serum creatinine and estimated GFR to rule out contrast-induced nephropathy risk.
• Hold metformin (if co-prescribed for a secondary indication) per ACR and ADA guidelines around contrast procedures.

Risk Domain 2: Renal Function and Gadolinium-Based Contrast

Romosozumab itself is not nephrotoxic at approved doses, and the FRAME trial (N=7,180) reported no clinically meaningful renal adverse event signal attributable to the drug. [4] However, GBCAs carry their own renal concern: nephrogenic systemic fibrosis (NSF) in patients with severely reduced kidney function (eGFR <30 mL/min/1.73m2). [5]

Because osteoporosis is most common in older postmenopausal women, many Evenity patients are in an age group where chronic kidney disease is prevalent. Before MRI with gadolinium, clinicians should obtain a current eGFR measurement. If eGFR is between 30 and 44 mL/min/1.73m2, use of a macrocyclic GBCA (gadobutrol, gadoteridol, or gadoterate meglumine) is preferred over linear agents per ACR guidance. [3]

Injection-Site Timing and Imaging Artifacts

One practical, under-discussed consideration: subcutaneous romosozumab injections can cause local soft-tissue changes visible on imaging. Injection sites in the abdomen or thigh may show focal hyperintensity on T2-weighted MRI sequences or a small area of soft-tissue density on CT within days of injection. Informing the radiologist of recent romosozumab injection location prevents misinterpretation as a soft-tissue lesion. This is not a pharmacological interaction but is a real diagnostic pitfall. [6]

A simple pre-imaging checklist for patients on romosozumab is outlined in the decision framework below:

Pre-Imaging Framework for Patients on Evenity

| Parameter | Iodinated CT/Angiography | Gadolinium MRI | |---|---|---| | Cardiovascular screen | Mandatory (boxed warning) | Recommended | | eGFR threshold | Assess if eGFR <60 (contrast nephropathy risk) | Mandatory; avoid GBCA if eGFR <30 | | GBCA agent preference | Not applicable | Macrocyclic preferred if eGFR 30 to 44 | | Injection-site disclosure | Disclose to radiologist | Disclose to radiologist | | Timing of romosozumab dose | No hold required | No hold required | | Calcium check | Recommended | Recommended |

Alcohol and Romosozumab: Can You Drink on Evenity?

No pharmacokinetic or pharmacodynamic interaction between alcohol and romosozumab appears in the FDA label or in the ARCH or FRAME trial adverse event reports. The two substances do not compete for the same metabolic pathways. [1][2][4]

Why Alcohol Still Matters on Evenity

Alcohol has a well-established dose-dependent negative effect on bone mineral density. A meta-analysis of 33 studies found that chronic heavy alcohol intake (more than 2 drinks per day) was associated with significantly lower BMD and higher fracture risk, while moderate consumption showed a more complex, slightly protective signal at some skeletal sites. [7]

Romosozumab is prescribed precisely to build bone in high-fracture-risk patients. Heavy alcohol use partially undermines that therapeutic goal by:

1. Suppressing osteoblast activity and bone formation.
2. Increasing falls risk through impaired balance and coordination.
3. Interfering with calcium and vitamin D absorption in the gut.

The National Osteoporosis Foundation (now part of Bone Health and Osteoporosis Foundation) recommends limiting alcohol to no more than 2 drinks per day for people with osteoporosis. [8] This recommendation applies whether or not a patient is on romosozumab.

Practical Guidance

Occasional, moderate alcohol consumption (1 to 2 standard drinks) does not require a hold on romosozumab injections and is not expected to alter drug efficacy based on current data. Patients who drink heavily should be counseled that alcohol blunts the bone-building effect they are trying to achieve with a costly, time-limited 12-month biologic course.

Other Clinically Relevant Romosozumab Interactions

Calcium Supplements and Vitamin D

The FDA label states that patients must receive adequate calcium and vitamin D during romosozumab therapy. Hypocalcemia is a contraindication. Subjects in FRAME received calcium 500 to 1,000 mg and vitamin D 600 to 800 IU daily. [4] Timing of calcium supplements relative to the monthly injection is not clinically restricted.

Sequential Antiresorptive Therapy

The sequence of osteoporosis agents matters. In the ARCH trial, patients transitioned from romosozumab to alendronate after 12 months showed a 48% reduction in new vertebral fracture risk at 24 months compared with alendronate alone from the start. [2] Denosumab is an alternative post-romosozumab agent. Stopping denosumab without a transition plan can cause rebound vertebral fractures, which is not a direct romosozumab interaction but is a critical sequencing issue when planning imaging follow-up for these patients.

Corticosteroids

Systemic corticosteroids accelerate bone loss and can worsen osteoporosis. No specific pharmacokinetic interaction with romosozumab has been documented, but concurrent corticosteroid use may reduce the net gain in bone mineral density. The American Society for Bone and Mineral Research (ASBMR) task force notes that anabolic agents including romosozumab are preferred first-line in glucocorticoid-induced osteoporosis at high fracture risk. [9]

NSAIDs and Aspirin

Non-steroidal anti-inflammatory drugs and aspirin do not interact pharmacokinetically with romosozumab. Aspirin may be prescribed concurrently for cardiovascular prophylaxis given the boxed warning. No adjustment to romosozumab dosing is needed. [1]

Denosumab

Combining two biological bone agents is not standard practice. No trials have evaluated concurrent denosumab and romosozumab. Sequential use is supported; concurrent use is not recommended due to theoretical additive hypocalcemia risk and lack of safety data. [1]

Clinical Evidence: The ARCH and FRAME Trials

ARCH Trial (N=4,093)

ARCH compared 12 months of romosozumab 210 mg monthly followed by alendronate versus alendronate alone from the start in postmenopausal women with osteoporosis and a prior vertebral fracture. At 24 months, the romosozumab-to-alendronate group had a 48% lower risk of new vertebral fracture (P<0.001) and a 27% lower risk of clinical fracture compared with the alendronate group. [2] The cardiovascular adverse event imbalance (2.5% serious cardiac ischemic events vs. 1.9%) led to the boxed warning.

FRAME Trial (N=7,180)

FRAME randomized postmenopausal women with low bone mineral density to romosozumab 210 mg monthly for 12 months followed by denosumab, versus placebo followed by denosumab. After 12 months of romosozumab, new vertebral fractures occurred in 0.5% of the romosozumab group versus 1.8% in the placebo group, a 73% relative risk reduction (P<0.001). [4] No significant cardiovascular imbalance was observed in FRAME, a distinction that has prompted extensive post-marketing analysis.

The FDA label notes: "In the ARCH study, an imbalance in positively adjudicated serious cardiovascular adverse events was observed. Do not initiate Evenity in patients who have had a myocardial infarction or stroke within the preceding year." [1]

Imaging Modalities Used to Monitor Romosozumab Therapy

Dual-Energy X-Ray Absorptiometry (DXA)

DXA is the standard tool for monitoring BMD on romosozumab. It does not use iodinated or gadolinium contrast and carries no interaction concern. The International Society for Clinical Densitometry (ISCD) recommends repeat DXA at 12 to 24 months after starting anabolic therapy. [10] DXA scans can be scheduled at any point in the monthly romosozumab cycle without timing adjustments.

High-Resolution Peripheral Quantitative CT (HR-pQCT)

HR-pQCT provides three-dimensional bone microarchitecture data and is used in research and some specialty centers to evaluate romosozumab's effects on trabecular and cortical bone. This modality does not use intravenous contrast.

Vertebral Fracture Assessment (VFA)

VFA is a low-dose lateral spine acquisition performed on the DXA table to identify existing vertebral fractures before and after therapy. No contrast agent is involved.

Contrast-Enhanced CT or MRI

When a patient on romosozumab needs contrast-enhanced imaging for an unrelated indication (e.g., abdominal CT for suspected malignancy, MRI for soft-tissue evaluation), the guidance outlined in the framework table above applies. No romosozumab dose hold is required for contrast procedures.

Special Populations and Imaging Considerations

Patients With Prior Cardiovascular Events

Romosozumab is contraindicated in patients who have had an MI or stroke in the preceding 12 months. If such a patient nonetheless presents for contrast imaging while on Evenity (e.g., due to prescribing outside guidelines), the radiologist and ordering clinician should coordinate closely. High-osmolality contrast agents and large bolus volumes may add additional cardiovascular stress in an already high-risk patient.

Patients With Chronic Kidney Disease

Postmenopausal women frequently have CKD stage 3. Before gadolinium contrast, eGFR testing within 30 days is recommended by the ACR for at-risk populations. [3] Romosozumab does not independently impair renal function, but CKD affects both contrast safety and bone metabolism (renal osteodystrophy), making integrated specialist review advisable.

Patients With Hypocalcemia Risk

Hypocalcemia is a contraindication to romosozumab. Contrast procedures involving bowel prep (oral sodium phosphate solutions) can acutely shift calcium and phosphate levels. Ensuring calcium is within normal limits before both romosozumab dosing and major contrast procedures is sound clinical practice.

Counseling Points for Patients on Evenity Awaiting Imaging

Patients often ask their prescribing clinician whether they need to pause Evenity before a scan. The short answer: no pause is required for contrast imaging. The longer answer involves several specific steps:

1. Inform the imaging center that you are on romosozumab (Evenity) and note the most recent injection sites.
2. Confirm that your kidney function has been checked recently, particularly if gadolinium MRI is planned.
3. Let your prescriber know about any chest pain, shortness of breath, or prior cardiac events before any contrast procedure.
4. Continue calcium and vitamin D supplements as prescribed; do not stop them in anticipation of imaging.
5. Avoid heavy alcohol use throughout your 12-month romosozumab course to protect the bone-building gains you are working toward.

What Clinicians Should Document

When a patient on romosozumab is referred for contrast-enhanced imaging, the referring note should include:

• Current romosozumab cycle number (month 1 through 12).
• Date of most recent 210 mg injection.
• Cardiovascular history, specifically any MI or stroke in the past 12 months.
• Current eGFR and serum calcium.
• Any co-prescribed antiplatelet, anticoagulant, or antihypertensive agents that interact with contrast-related hemodynamic changes.

The ACR and the American College of Cardiology both note that documentation of cardiovascular risk factors is best practice before any contrast procedure, regardless of concurrent medications. [3][11]